|
[1]
|
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396(10258):1223 − 49. http://dx.doi.org/10.1016/S0140-6736(20)30752-2CrossRef
|
|
[2]
|
Sundström J, Lind L, Nowrouzi S, Hagström E, Held C, Lytsy P, et al. Heterogeneity in blood pressure response to 4 antihypertensive drugs: a randomized clinical trial. JAMA 2023;329(14):1160 − 9. http://dx.doi.org/10.1001/jama.2023.3322CrossRef
|
|
[3]
|
Zhang M, Shi Y, Zhou B, Huang ZJ, Zhao ZP, Zhao ZP, et al. Prevalence, awareness, treatment, and control of hypertension in China, 2004-18: findings from six rounds of a national survey. BMJ 2023;380:e071952. http://dx.doi.org/10.1136/bmj-2022-071952CrossRef
|
|
[4]
|
Tanira MOM, Al Balushi KA. Genetic variations related to hypertension: a review. J Hum Hypertens 2005;19(1):7 − 19. http://dx.doi.org/10.1038/sj.jhh.1001780CrossRef
|
|
[5]
|
Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet 2011;43(6):531 − 8. http://dx.doi.org/10.1038/ng.834CrossRef
|
|
[6]
|
Padmanabhan S, Dominiczak AF. Genomics of hypertension: the road to precision medicine. Nat Rev Cardiol 2021;18(4):235 − 50. http://dx.doi.org/10.1038/s41569-020-00466-4CrossRef
|
|
[7]
|
Schwartz GL, Turner ST. Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 2004;4(3):151 − 60. http://dx.doi.org/10.2165/00129785-200404030-00002CrossRef
|
|
[8]
|
Fontana V, Luizon MR, Sandrim VC. An update on the pharmacogenetics of treating hypertension. J Hum Hypertens 2015;29(5):283 − 91. http://dx.doi.org/10.1038/jhh.2014.76CrossRef
|
|
[9]
|
Krebs K, Milani L. Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. Hum Genomics 2019;13(1):39. http://dx.doi.org/10.1186/s40246-019-0229-zCrossRef
|
|
[10]
|
Swen JJ, van der Wouden CH, Manson LEN, Abdullah-Koolmees H, Blagec K, Blagus T, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet 2023;401(10374):347 − 56. http://dx.doi.org/10.1016/S0140-6736(22)01841-4CrossRef
|
|
[11]
|
Zhu C. Demand for direct-to-consumer genetic testing services in China and its implications for precision public health - China, 2021. China CDC Wkly 2022;4(32):715 − 9. http://dx.doi.org/10.46234/ccdcw2022.149CrossRef
|
|
[12]
|
Pharmacogenomic Examination and Management of hypertension patients in China based on antihypertensive efficacy and adverse reactions. 2022. http://www.china-pem.org.cn/. [2023-6-15]. (In Chinese). http://www.china-pem.org.cn/ |
|
[13]
|
China PEACE Collaborative Group, Zhou TT, Wang YF, Zhang HB, Wu CQ, Tian N, et al. Primary care institutional characteristics associated with hypertension awareness, treatment, and control in the China PEACE-Million Persons Project and primary health-care survey: a cross-sectional study. Lancet Glob Health 2023;11(1):e83 − 94. http://dx.doi.org/10.1016/S2214-109X(22)00428-4CrossRef
|
|
[14]
|
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021;398(10304):957 − 80. http://dx.doi.org/10.1016/S0140-6736(21)01330-1CrossRef
|
|
[15]
|
Rison SC, Carvalho C, Rull G, Robson J. Investigating hypertension in younger patients. BMJ 2022;376:e067924. http://dx.doi.org/10.1136/bmj-2021-067924CrossRef
|
|
[16]
|
General Office of the State Council. China’s medium-to-long term plan for the prevention and treatment of chronic diseases (2017-2025). 2017. https://www.gov.cn/zhengce/content/2017-02/14/content_5167886.htm. [2023-6-15]. (In Chinese). https://www.gov.cn/zhengce/content/2017-02/14/content_5167886.htm |
|
[17]
|
National Health Commission, State Administration of Traditional Chinese Medicine. Notice on further strengthening medication safety management and improving the level of rational drug use. 2022. https://www.gov.cn/zhengce/zhengceku/2022-07/30/content_5703604.htm. [2023-6-15]. (In Chinese). https://www.gov.cn/zhengce/zhengceku/2022-07/30/content_5703604.htm |